Dr. Saltzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6780 Mayfield road
Mayfield Heights, OH 44124Phone+1 440-312-4569Fax+1 440-312-6687
Summary
- Dr. Joel Saltzman is an oncologist in Mayfield Heights, OH and is affiliated with multiple hospitals in the area, including Hillcrest Hospital and CLeveland Clinic. He received his medical degree from Ohio State University College of Medicine and has been in practice 20 years. He specializes in gastrointestinal cancer, genitourinary oncology, and hematologic oncology and is experienced in neuro-oncology, amyloidosis, hematologic oncology, breast cancer, and prostate cancer.
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1997 - 2000
- Ohio State University College of MedicineClass of 1997
Certifications & Licensure
- OH State Medical License 1998 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012
- Top MD Consumers Checkbook
Clinical Trials
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
- Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Publications & Presentations
PubMed
- 5 citationsEfficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve
Cancer Discovery. 2024-06-03 - 13 citationsA Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.Folashade Otegbeye, Brenda Cooper, Paolo Caimi, Kayla Zamborsky, Jane Reese-Koc
Transplantation and Cellular Therapy. 2022-05-01 - 4 citationsAssociations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract C...Lauren F Huang, Augustine Hong, Gino Cioffi, Asrar Alahmadi, Tin-Yun Tang
Frontiers in Oncology. 2022-01-01
Press Mentions
- New Therapy Gives Hope to Dementia Patients, Their Families and CaregiversJuly 16th, 2021
- Determining Which Clinical Trial Is Best for YouJuly 16th, 2021
- New Technology Uses Genetic Testing to Help Millions Find the Perfect Clinical Trial MatchJuly 12th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: